# US 2026/0061085 A1 · Cyclic peptide and preparation method therefor, and complex comprising same and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061085 A1
- Document ID: US20260061085A1
- Status: Published application
- Kind: A1
- Application number: 19/107,124
- Filed: 2023-09-01
- Published: 2026-03-05
- Earliest claimed: 2022-09-02
- Applicants: Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
- Inventors: Changyu SHAN; Dexing ZENG; Yinfei CHEN; Wenjie LI
- Web page: https://patentgrep.com/patent/US20260061085A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61P 35/00: Antineoplastic agents
- C07K 1/02: in solution {(C07K1/003, C07K1/006 take precedence)}
- C07K 1/061: {using protecting groups}
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 2121/00: Preparations for use in therapy
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is a cyclic peptide, having a sequence of cyclo(X1X2X3X4X5X6), wherein X1 is asparagine; X2 is glycine or sarcosine; X3 is arginine; X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine; X5 is lysine; and X6 is selected from a group consisting of tyrosine, valine, and glutamic acid. Provided is a method for preparing the cyclic peptide. Provided is a complex, comprising the cyclic peptide, a linker, and a chelating agent. Provided is a use of the complex as a radionuclide-labeled targeting molecule. Provided is a radionuclide labeling method, comprising contacting a complex that chelates a radionuclide with an object to be labeled by the radionuclide.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A cyclic peptide, having a sequence of cyclo (X1X2X3X4X5X6), wherein
the X1 is asparagine;
the X2 is sarcosine or glycine;
the X3 is arginine;
the X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine;
the X5 is lysine; and
the X6 is selected from a group consisting of tyrosine, valine, and glutamic acid.

### Claim 12 (depends on 11)

The cyclic peptide according to claim 11, wherein
the X4 is L-threonine or D-threonine, and/or
the X6 is L-tyrosine or D-tyrosine.

### Claim 13 (depends on 11)

The cyclic peptide according to claim 11, wherein
the X1 is L-asparagine;
the X3 is L-arginine;
the X4 is L-threonine;
the X5 is L-lysine; or
the X6 is L-tyrosine.

### Claim 14 (depends on 11)

The cyclic peptide according to claim 11, wherein
the X1 is L-asparagine;
the X3 is L-arginine;
the X4 is L-threonine;
the X5 is L-lysine; and
the X6 is L-tyrosine.

### Claim 15 (depends on 11)

The cyclic peptide according to claim 11, wherein
the X1 is L-asparagine,
the X2 is sarcosine,
the X3 is L-arginine,
the X4 is L-threonine,
the X5 is L-lysine, and
the X6 is L-tyrosine.

### Claim 16 (depends on 11)

The cyclic peptide according to claim 11, wherein
the X1 is L-asparagine,
the X2 is glycine,
the X3 is L-arginine,
the X4 is L-threonine,
the X5 is L-lysine, and
the X6 is L-tyrosine.

### Claim 17 (depends on 11)

The cyclic peptide according to claim 11 coupled to a linker coupled to a chelating agent.

### Claim 18 (depends on 17)

The cyclic peptide according to claim 17, wherein the linker is polyethylene glycol.

### Claim 19 (depends on 17)

The cyclic peptide according to claim 17, wherein the chelating agent is selected from, and comprises or consists of at least one selected from a group consisting of ions formed by reducing one or more hydrogen ions of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid, 1,4,7-triazacyclononane-N,N′,N″-triacetic acid, diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid, 2,2′-((6-amino-1-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)hexan-2-yl)azanediyl)diacetic acid, 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, ethylenebis(o-hydroxyphenyl)glycine, N,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid, 1,4,7,10-tetraazacyclododecane-α,α′,α″,α′″-tetramethyl-N,N′,N″,N′″-tetraacetic acid, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-(methyltetraacetic acid) ethylenediaminetetraacetic acid (FDTA), 1,3-propylenediaminetetraacetic acid (PDTA), triethylenetetraaminehexaacetic acid (TTHA), 1,5,10-N,N′,N″-tris(2,3-dihydroxybenzoyl)-tricatecholate, 1,3,5-N,N′,N″-tris(2,3-dihydroxybenzoyl)aminomethylbenzene, and 6-hydrazinonicotinic acid.

### Claim 20 (depends on 17)

The cyclic peptide according to claim 17, wherein the chelating agent comprises 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′-tetraacetic acid.

### Claim 21 (depends on 11)

A complex, comprising:
the cyclic peptide according to claim 11;
a linker, coupled to the cyclic peptide; and
a chelating agent, coupled to the linker.

### Claim 22 (depends on 11)

A method of radionuclide labeling in a subject, comprising administering the cyclic peptide according to claim 11 to the subject.

### Claim 23 (depends on 11)

A drug carrier, comprising the cyclic peptide according to claim 11.

### Claim 24 (depends on 11)

A radionuclide formulation, comprising:
the cyclic peptide according to claim 11;
a linker, coupled to the cyclic peptide;
a chelating agent, coupled to the linker; and
a radionuclide chelated by the chelating agent.

### Claim 25 (depends on 24)

The radionuclide formulation according to claim 24, wherein the radionuclide is selected from at least one of a group consisting of 44Sc, 47Sc, 64Cu, 67Cu, 67Ga, 68Ga, 99mTc, 90Y, 111In, 177Lu, 212Pb, 213Bi, and 225Ac.

### Claim 26 (depends on 24)

The radionuclide formulation according to claim 24, wherein the radionuclide is 68Ga.

### Claim 27 (depends on 11)

A method of detecting cancer, diagnosing cancer, monitoring cancer progression, monitoring treatment of cancer, or treating cancer, of a subject, comprising administering the cyclic peptide according to claim 11 to the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cancer is selected from a group consisting of head and neck cancer, liver cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, endometrial cancer, cervical cancer, prostate cancer, adrenal cancer, lymphoma, salivary gland cancer, bone cancer, brain cancer, cerebellar cancer, colon cancer, rectal cancer, colorectal cancer, oronasopharyngeal cancer, kidney cancer, bladder cancer, skin cancer, melanoma, basal cell carcinoma, hard palate cancer, tongue squamous cell cancer, meningioma, pleomorphic adenoma, astrocytoma, soft tissue sarcoma, chondrosarcoma, cortical adenoma, mesothelioma, squamous cell carcinoma, and adenocarcinoma.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer is selected from a group consisting of breast cancer, ovarian cancer, thyroid cancer, pancreatic cancer, colorectal cancer, non-small cell lung cancer, and osteosarcoma.

### Claim 30 (depends on 28)

The method of claim 28, wherein the cancer is a tumor with high expression of CD13.
